Topics

These highlights do not include all the information needed to use ASTELIN safely and effectively. See full prescribing information for ASTELIN. ASTELIN (azelastine hydrochloride) nasal spray Initial U.S. Approval: 1996 | Astelin [Meda Pharmaceuticals] | BioPortfolio

12:37 EST 27th January 2019 | BioPortfolio
Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Astelin Nasal Spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 5 years and older, and for the treatment of the symptoms of vasomotor rhinitis in adults and adolescent patients 12 years and older.

The recommended dosage of Astelin Nasal Spray in adults and adolescent patients 12 years and older with seasonal allergic rhinitis is one or two sprays per nostril twice daily. The recommended dosage of Astelin Nasal Spray in pediatric patients 5 years to 11 years of age is one spray per nostril twice daily.

The recommended dosage of Astelin Nasal Spray in adults and adolescent patients 12 years and older with vasomotor rhinitis is two sprays per nostril twice daily.

Administer Astelin Nasal Spray by the intranasal route only.

Prime Astelin Nasal Spray before initial use by releasing 4 sprays or until a fine mist appears. When Astelin Nasal Spray has not been used for 3 or more days, reprime with 2 sprays or until a fine mist appears. Avoid spraying Astelin Nasal Spray into the eyes.

Astelin Nasal Spray is a nasal spray solution. Each spray of Astelin Nasal Spray delivers a volume of 0.137 mL solution containing 137 mcg of azelastine hydrochloride.

None.

In clinical trials, the occurrence of somnolence has been reported in some patients taking Astelin Nasal Spray [see Adverse Reactions (6.1) ]. Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness and motor coordination such as operating machinery or driving a motor vehicle after administration of Astelin Nasal Spray. Concurrent use of Astelin Nasal Spray with alcohol or other central nervous system depressants should be avoided because additional reductions in alertness and additional impairment of central nervous system performance may occur [see Drug Interactions (7.1) ].

Use of Astelin Nasal Spray has been associated with somnolence [see Warnings and Precautions (5.1) ].

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect rates observed in practice.

Adverse experience information for Astelin Nasal Spray is derived from six placebo- and active-controlled, 2-day to 8-week clinical trials which included 391 patients, 12 years of age and older, with seasonal allergic rhinitis who received Astelin Nasal Spray at a dose of 2 sprays per nostril twice daily. In placebo-controlled efficacy trials, the incidence of discontinuation due to adverse reactions in patients receiving Astelin Nasal Spray and vehicle placebo was 2.2% and 2.8%, respectively.

Table 1 contains adverse reactions that were reported with frequencies ≥2% in the Astelin Nasal Spray 2 sprays per nostril twice daily treatment group and more frequently than placebo.

Table 1: Adverse Reactions Reported in ≥2% Incidence in Placebo-Controlled
Trials in Patients with Seasonal Allergic Rhinitis [n (%)]
Astelin
Nasal Spray
N = 391
Vehicle
Placebo
N = 353
Bitter Taste 77 (19.7%) 2 (0.6%)
Headache 58 (14.8%) 45 (12.7%)
Somnolence 45 (11.5%) 19 (5.4%)
Nasal Burning 16 (4.1%) 6 (1.7%)
Pharyngitis 15 (3.8%) 10 (2.8%)
Paroxysmal Sneezing 12 (3.1%) 4 (1.1%)
Dry Mouth 11 (2.8%) 6 (1.7%)
Nausea 11 (2.8%) 4 (1.1%)
Rhinitis 9 (2.3%) 5 (1.4%)
Fatigue 9 (2.3%) 5 (1.4%)
Dizziness 8 (2.0%) 5 (1.4%)
Epistaxis 8 (2.0%) 5 (1.4%)
Weight Increase 8 (2.0%) 0 (0.0%)

Adverse experience information for Astelin Nasal Spray at a dose of one spray per nostril twice daily is derived from two placebo-controlled 2-week clinical studies which included 276 patients 12 years of age and older with seasonal allergic rhinitis. The incidence of discontinuation due to adverse reactions in patients receiving Astelin Nasal Spray and vehicle placebo was 0.0% and 0.8%, respectively. Bitter taste was reported in 8.3% of patients compared to none in the placebo group. Somnolence was reported in 0.4% of patients compared to none in the placebo group.

A total of 176 patients 5 to 11 years of age were exposed to Astelin Nasal Spray at a dose of 1 spray each nostril twice daily in 3 placebo-controlled studies. In these studies, adverse reactions that occurred more frequently in patients treated with Astelin Nasal Spray than with placebo, and that were not represented in the adult adverse reactions table above include rhinitis/cold symptoms (17.0% vs. 9.5%), cough (11.4% vs. 8.3%), conjunctivitis (5.1% vs. 1.8%), and asthma (4.5% vs. 4.1%).

The following reactions were observed infrequently (<2% and exceeding placebo incidence) in patients who received Astelin Nasal Spray dosed at 1 or 2 sprays per nostril twice daily in U.S. clinical trials.

Cardiovascular: flushing, hypertension, tachycardia.

Dermatological: contact dermatitis, eczema, hair and follicle infection, furunculosis, skin laceration.

Digestive: constipation, gastroenteritis, glossitis, ulcerative stomatitis, vomiting, increased SGPT, aphthous stomatitis, diarrhea, toothache.

Metabolic and Nutritional: increased appetite.

Musculoskeletal: myalgia, temporomandibular dislocation, rheumatoid arthritis.

Neurological: hyperkinesia, hypoesthesia, vertigo.

Psychological: anxiety, depersonalization, depression, nervousness, sleep disorder, thinking abnormal.

Respiratory: bronchospasm, coughing, throat burning, laryngitis, bronchitis, dry throat, nocturnal dyspnea, nasopharyngitis, nasal congestion, pharyngolaryngeal pain, sinusitis, nasal dryness, paranasal sinus hypersecretion, post nasal drip.

Special Senses: conjunctivitis, eye abnormality, eye pain, watery eyes, taste loss.

Urogenital: albuminuria, amenorrhea, breast pain, hematuria, increased urinary frequency.

Whole Body: allergic reaction, back pain, herpes simplex, viral infection, malaise, pain in extremities, abdominal pain, pyrexia.

Adverse experience information for Astelin Nasal Spray is derived from two placebo-controlled clinical studies which included 216 patients 12 years and older with vasomotor rhinitis who received Astelin Nasal Spray at a dose of 2 sprays per nostril twice daily for up to 28 days. The incidence of discontinuation due to adverse reactions in patients receiving Astelin Nasal Spray and vehicle placebo was 2.8% and 2.9%, respectively.

The following adverse reactions were reported with frequencies ≥ 2% in the Astelin Nasal Spray treatment group and more frequently than placebo.

Reactions observed infrequently (<2% and exceeding placebo incidence) in patients who received Astelin Nasal Spray (2 sprays/nostril twice daily) in U.S. clinical trials in vasomotor rhinitis were similar to those observed in U.S. clinical trials in seasonal allergic rhinitis.

In controlled trials involving nasal and oral azelastine hydrochloride formulations, there were infrequent occurrences of hepatic transaminase elevations.

Table 2: Adverse Reactions Reported in ≥2% Incidence in Placebo-Controlled
Trials in Patients with Vasomotor Rhinitis [n (%)]
Astelin
Nasal Spray
N = 216
Vehicle
Placebo
N = 210
Bitter Taste 42 (19.4%) 5 (2.4%)
Headache 17 (7.9%) 16 (7.6%)
Dysesthesia 17 (7.9%) 7 (3.3%)
Rhinitis 12 (5.6%) 5 (2.4%)
Epistaxis 7 (3.2%) 5 (2.4%)
Sinusitis 7 (3.2%) 4 (1.9%)
Somnolence 7 (3.2%) 2 (1.0%)

During the post approval use of Astelin Nasal Spray, the following adverse reactions have been identified. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions reported include: anaphylaxis, application site irritation, atrial fibrillation, chest pain, confusion, dyspnea, facial edema, involuntary muscle contractions, nasal sores, palpitations, paresthesia, parosmia, pruritus, rash, disturbance or loss of sense of smell and/or taste, tolerance, urinary retention, vision abnormal and xerophthalmia.

Concurrent use of Astelin Nasal Spray with alcohol or other central nervous system depressants should be avoided because reductions in alertness and impairment of central nervous system performance may occur [see Warnings and Precautions (5.1) ].

Limited data from postmarketing experience over decades of use with Astelin in pregnant women have not identified any drug associated risks of miscarriage, birth defects, or other adverse maternal or fetal outcomes. In animal reproduction studies, there was no evidence of fetal harm at oral doses approximately 5 times the clinical daily dose.  Oral administration of azelastine hydrochloride to pregnant mice, rats, and rabbits, during the period of organogenesis, produced developmental toxicity that included structural abnormalities, decreased embryo-fetal survival, and decreased fetal body weights at doses 270 times and higher than the maximum recommended human daily intranasal dose (MRHDID) of 1.096 mg. However, the relevance of these findings in animals to pregnant women was considered questionable based upon the high animal to human dose multiple. 

The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

In an embryo-fetal development study in mice dosed during the period of organogenesis, azelastine hydrochloride caused embryo-fetal death, structural abnormalities (cleft palate; short or absent tail; fused, absent or branched ribs), delayed ossification, and decreased fetal weight at approximately 300 times the maximum recommended human daily intranasal dose (MRHDID) in adults (on a mg/m basis at a maternal oral dose of 68.6 mg/kg/day), which also caused maternal toxicity as evidenced by decreased maternal body weight. Neither fetal nor maternal effects occurred in mice at approximately 15 times the MRHDID in adults (on a mg/mbasis at a maternal oral dose of 3 mg/kg/day).

In an embryo-fetal development study in pregnant rats dosed during the period of organogenesis from gestation days 7 to 17, azelastine hydrochloride caused structural abnormalities (oligo-and brachydactylia), delayed ossification, and skeletal variations, in the absence of maternal toxicity, at approximately 270 times the MRHDID in adults (on a mg/m basis at a maternal oral dose of 30 mg/kg/day). Azelastine hydrochloride caused embryo-fetal death and decreased fetal weight and severe maternal toxicity at approximately 610 times the MRHDID (on a mg/m basis at a maternal oral dose of 68.6 mg/kg/day). Neither fetal nor maternal effects occurred at approximately 20 times the MRHDID (on a mg/mbasis at a maternal oral dose of 2 mg/kg/day).

In an embryo-fetal development study in pregnant rabbits dosed during the period of organogenesis from gestation days 6 to 18, azelastine hydrochloride caused abortion, delayed ossification and decreased fetal weight and severe maternal toxicity at approximately 530 times the MRHDID in adults (on a mg/mbasis at a maternal oral dose of 30 mg/kg/day). Neither fetal nor maternal effects occurred at approximately 5 times the MRHDID (on a mg/mbasis at a maternal oral dose of 0.3 mg/kg/day).

In a prenatal and postnatal development study in pregnant rats dosed from late in the gestation period and through the lactation period from gestation day 17 through lactation day 21, azelastine hydrochloride produced no adverse developmental effects on pups at maternal doses up to approximately 270 times the MRHDID (on mg/m basis at a maternal dose of 30 mg/kg/day).

There are no data on the presence of azelastine hydrochloride in human milk, the effects on the breastfed infant, or the effects on milk production. Breastfed infants should be monitored for signs of milk rejection during Astelin use by lactating women (see Clinical Considerations). The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Astelin and any potential adverse effects on the breastfed infant from Astelin or from the underlying maternal condition.

Breastfed infants of lactating women treated with Astelin should be monitored for possible signs of milk rejection related to the bitter taste of azelastine hydrochloride.

The safety and effectiveness of Astelin Nasal Spray for the treatment of symptoms of seasonal allergic rhinitis have been established for patients 5 years and older [see Adverse Reactions (6.1) and Clinical Studies (14.1) ]. The safety and effectiveness of Astelin Nasal Spray for the treatment of vasomotor rhinitis have been established for patients 12 years and older [see Adverse Reactions (6.1) and Clinical Studies (14.2) ]. The safety and effectiveness of Astelin Nasal Spray in pediatric patients below the age of 5 years with seasonal allergic rhinitis and in pediatric patients below the age of 12 years with vasomotor rhinitis have not been established.

Clinical trials of Astelin Nasal Spray did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

There have been no reported overdosages with Astelin Nasal Spray. Acute overdosage by adults with this dosage form is unlikely to result in clinically significant adverse reactions, other than increased somnolence, since one bottle of Astelin Nasal Spray contains 30 mg of azelastine hydrochloride. Clinical trials in adults with single doses of the oral formulation of azelastine hydrochloride (up to 16 mg) have not resulted in increased incidence of serious adverse reactions. General supportive measures should be employed if overdosage occurs. There is no known antidote to Astelin Nasal Spray. Oral ingestion of antihistamines has the potential to cause serious adverse effects in young children. Accordingly, Astelin Nasal Spray should be kept out of the reach of children.

Astelin (azelastine hydrochloride) Nasal Spray, 137 micrograms (mcg), is an antihistamine formulated as a metered-spray solution for intranasal administration. Azelastine hydrochloride occurs as a white, almost odorless, crystalline powder with a bitter taste. It has a molecular weight of 418.37. It is sparingly soluble in water, methanol, and propylene glycol and slightly soluble in ethanol, octanol, and glycerine. It has a melting point of about 225°C and the pH of a saturated solution is between 5.0 and 5.4. Its chemical name is (±)-1-(2H)-phthalazinone,4-[(4-chlorophenyl) methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-, monohydrochloride. Its molecular formula is CHClNO•HCl with the following chemical structure:

Astelin Nasal Spray contains 0.1% azelastine hydrochloride in an aqueous solution at pH 6.8 ± 0.3. It also contains benzalkonium chloride (125 mcg/mL), edetate disodium, hypromellose, citric acid, dibasic sodium phosphate, sodium chloride, and purified water.

After priming [see Dosage and Administration (2.3) ], each metered spray delivers a 0.137 mL mean volume containing 137 mcg of azelastine hydrochloride (equivalent to 125 mcg of azelastine base). The bottle can deliver 200 metered sprays.

Azelastine hydrochloride, a phthalazinone derivative, exhibits histamine H-receptor antagonist activity in isolated tissues, animal models, and humans. Astelin Nasal Spray is administered as a racemic mixture with no difference in pharmacologic activity noted between the enantiomers in in vitro studies. The major metabolite, desmethylazelastine, also possesses H-receptor antagonist activity.

In a placebo-controlled study (95 subjects with allergic rhinitis), there was no evidence of an effect of Astelin Nasal Spray (2 sprays per nostril twice daily for 56 days) on cardiac repolarization as represented by the corrected QT interval (QTc) of the electrocardiogram. Following multiple dose oral administration of azelastine 4 mg or 8 mg twice daily, the mean change in QTc was 7.2 msec and 3.6 msec, respectively.

Interaction studies investigating the cardiac repolarization effects of concomitantly administered oral azelastine hydrochloride and erythromycin or ketoconazole were conducted. These drugs had no effect on QTc based on analysis of serial electrocardiograms. At a dose approximately 8 times the maximum recommended dose, azelastine hydrochloride does not prolong the QTc interval to any clinically relevant extent.

After intranasal administration, the systemic bioavailability of azelastine hydrochloride is approximately 40%. Maximum plasma concentrations (C) are achieved in 2-3 hours.

Azelastine hydrochloride administered intranasally at doses above two sprays per nostril twice daily for 29 days resulted in greater than proportional increases in C and area under the curve (AUC) for azelastine.

Based on intravenous and oral administration, the steady-state volume of distribution is 14.5 L/kg. In vitro studies with human plasma indicate that the plasma protein binding of azelastine and its metabolite, desmethylazelastine, are approximately 88% and 97%, respectively.

Azelastine is oxidatively metabolized to the principal active metabolite, desmethylazelastine, by the cytochrome P450 enzyme system. The specific P450 isoforms responsible for the biotransformation of azelastine have not been identified. After intranasal dosing of azelastine hydrochloride to steady-state, plasma concentrations of desmethylazelastine range from 20-50% of azelastine concentrations. Limited data indicate that the metabolite profile is similar when azelastine hydrochloride is administered via the intranasal or oral route.

Based on intravenous and oral administration, the elimination half-life and plasma clearance are 22 hours and 0.5 L/h/kg, respectively. Approximately 75% of an oral dose of radiolabeled azelastine hydrochloride was excreted in the feces with less than 10% as unchanged azelastine.

Following oral administration, pharmacokinetic parameters were not influenced by hepatic impairment.

Based on oral, single-dose studies, renal insufficiency (creatinine clearance <50 mL/min) resulted in a 70-75% higher C and AUC compared to normal subjects. Time to maximum concentration was unchanged.

Following oral administration, pharmacokinetic parameters were not influenced by age.

Following oral administration, pharmacokinetic parameters were not influenced by gender.

The effect of race has not been evaluated.

No significant pharmacokinetic interaction was observed with the co-administration of orally administered azelastine (4 mg twice daily) with erythromycin (500 mg three times daily for 7 days). In this study, co-administration of orally administered azelastine with erythromycin resulted in C of 5.36 ± 2.6 ng/mL and AUC of 49.7 ± 24 ng•h/mL for azelastine, whereas, administration of azelastine alone resulted in C of 5.57 ± 2.7 ng/mL and AUC of 48.4 ± 24 ng•h/mL for azelastine.

In a multiple-dose, steady-state drug interaction trial in healthy subjects, cimetidine (400 mg twice daily) increased orally administered mean azelastine (4 mg twice daily) concentrations by approximately 65%. No pharmacokinetic interaction was observed with co-administration of orally administered azelastine (4 mg twice daily) with ranitidine hydrochloride (150 mg twice daily). Oral co-administration of azelastine with ranitidine resulted in C of 8.89 ±3.28 ng/mL and AUC of 88.22 ± 40.43 ng•h/mL for azelastine, whereas, azelastine when administered alone resulted in C of 7.83 ± 4.06 ng/mL and AUC of 80.09 ± 43.55 ng•h/mL for azelastine.

No significant pharmacokinetic interaction was observed with the co-administration of an oral 4 mg dose of azelastine hydrochloride twice daily and theophylline 300 mg or 400 mg twice daily.

Two-year carcinogenicity studies in Crl:CD(SD)BR rats and NMRI mice were conducted to assess the carcinogenic potential of azelastine hydrochloride. No evidence of tumorigenicity was observed in rats at doses up to 30 mg/kg day (approximately 270 and 240 times the MRHDID for adults and children, respectively, on a mg/m basis). No evidence for tumorigenicity was observed in mice at doses up to 25 mg/kg (approximately 110 and 100 times the MRHDID for adults and children, respectively, on a mg/m basis).

Azelastine hydrochloride showed no genotoxic effects in the Ames test, DNA repair test, mouse lymphoma forward mutation assay, mouse micronucleus test, or chromosomal aberration test in rat bone marrow.

There were no effects on male or female fertility and reproductive performance in male and female rats at oral doses up to 30 mg/kg (approximately 270 times the MRHDID in adults on a mg/mbasis). At 68.6 mg/kg (approximately 610 times the MRHDID on a mg/mbasis), the duration of estrous cycles was prolonged and copulatory activity and the number of pregnancies were decreased. The numbers of corpora lutea and implantations were decreased; however, pre-implantation loss was not increased.

The efficacy and safety of Astelin Nasal Spray were evaluated in three placebo-controlled clinical trials of Astelin Nasal Spray including 322 patients with seasonal allergic rhinitis who received two sprays per nostril twice a day for up to 4 weeks. These trials included 55 pediatric patients ages 12 to 16 years. Assessment of efficacy was based on the 12-hour reflective Total Symptom Complex (TSC) and Major Symptom Complex (MSC). The MSC was calculated as the average of individual symptoms of nose blows, sneezes, runny nose/sniffles, itchy nose, and watery eyes as assessed by patients on a 0-5 categorical scale. Astelin Nasal Spray two sprays per nostril twice daily demonstrated a greater decrease in the MSC than placebo (Table 3).

In dose-ranging trials, administration of Astelin Nasal Spray two sprays per nostril twice daily resulted in a statistically significant decrease in symptoms compared to saline placebo within 3 hours after initial dosing and persisted over the 12-hour dosing interval.

Table 3: Mean Change from Baseline in Reflective MSCMajor Symptom Complex (MSC): Average of individual symptoms of nose blows, sneezes, runny nose/sniffles, itchy nose, and watery eyes as assessed by patients on a 0-5 categorical scale. in Adults and Adolescents ≥12 Years with Seasonal Allergic Rhinitis Treated with Astelin Nasal Spray Two Sprays Per Nostril Twice Daily Versus Placebo
Treatment N Baseline
LS Mean
(SD)
Change from
Baseline
(SD)
Treatment
Difference
P-value
Trial 1: 12 Hour AM and PM Reflective MSC
Astelin Nasal Spray 63 11.48 (4.13) -3.05 (3.51) 1.98 <0.01
Placebo Nasal Spray 60 10.84 (4.53) -1.07 (3.52)
Trial 2: 12 Hour AM and PM Reflective MSC
Astelin Nasal Spray 63 12.50 (4.5) -4.10 (3.46) 2.03 <0.01
Placebo Nasal Spray 63 12.18 (4.64) -2.07 (4.01)
Trial 3: 12 Hour AM and PM Reflective MSC
Astelin Nasal Spray 66 12.04 (4.03) -3.31 (3.74) 1.35 0.04
Placebo Nasal Spray 66 11.66 (3.96) -1.96 (3.57)

The efficacy and safety of Astelin Nasal Spray were evaluated in two placebo-controlled clinical trials of Astelin Nasal Spray including 275 patients with seasonal allergic rhinitis who received one spray per nostril twice a day for up to 2 weeks. Assessment of efficacy was based on the 12-hour reflective Total Nasal Symptom Score [rTNSS]. rTNSS is calculated as the sum of the patients scoring of four individual nasal symptoms (runny nose, sneezing, itchy nose, and nasal congestion) as assessed by patients on a 0-3 categorical scale. The primary efficacy endpoint was the change from Baseline to Day 14 in rTNSS. The mean change from baseline in rTNSS was greater in patients receiving Astelin Nasal Spray one spray per nostril twice daily than those receiving placebo (Table 4).

Two-week studies comparing the efficacy (and safety) of Astelin Nasal Spray two sprays per nostril twice daily versus one spray per nostril twice daily were not conducted.

Table 4: Mean Change from Baseline in Reflective TNSSTotal Nasal Symptom Score (TNSS): Average of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestion as assessed by patients on a 0-3 categorical scale. in Adults and Adolescents ≥12 years with Seasonal Allergic Rhinitis Treated with Astelin Nasal Spray One Spray Per Nostril Twice Daily Versus Placebo
Treatment N Baseline
LS Mean
(SD)
Change from
Baseline
(SD)
Treatment
Difference
P-value
Trial 4: 12 Hour AM and PM Reflective TNSS
Astelin Nasal Spray 138 16.34 (4.22) -2.69 (4.79) 1.38 0.01
Placebo Nasal Spray 141 17.21 (4.32) -1.31 (4.29)
Trial 5: 12 Hour AM and PM Reflective TNSS
Astelin Nasal Spray 137 16.62 (4.20) -3.68 (4.16) 1.18 0.02
Placebo Nasal Spray 136 16.84 (4.77) -2.50 (4.01)

The efficacy and safety of Astelin Nasal Spray were evaluated in two placebo-controlled clinical trials of Astelin Nasal Spray including 216 patients with vasomotor rhinitis who received two sprays per nostril twice a day for up to 4 weeks. These patients had vasomotor rhinitis for at least one year, negative skin tests to indoor and outdoor aeroallergens, negative nasal smears for eosinophils, and negative sinus X-rays. Astelin Nasal Spray demonstrated a significantly greater decrease in a symptom complex comprised of rhinorrhea, post nasal drip, nasal congestion, and sneezing compared to placebo.

Astelin (azelastine hydrochloride) Nasal Spray, 137 mcg is supplied as a 30-mL package (NDC 0037-0241-30) delivering 200 metered sprays in a high-density polyethylene (HDPE) bottle fitted with a metered-dose spray pump unit. The spray pump unit consists of a nasal spray pump fitted with a blue safety clip and a blue plastic dust cover. The net content of the bottle is 30 mL (net weight 30 gm of solution). Each bottle contains 30 mg (1 mg/mL) of azelastine hydrochloride. After priming [see Dosage and Administration (2.3) ], each spray delivers a fine mist containing a mean volume of 0.137 mL solution containing 137 mcg of azelastine hydrochloride. The correct amount of medication in each spray cannot be assured before the initial priming and after 200 sprays have been used, even though the bottle is not completely empty. The bottle should be discarded after 200 sprays have been used. Astelin Nasal Spray should not be used after the expiration date "EXP" printed on the medicine label and carton.

Storage:

Store at controlled room temperature 20° to 25°C (68° to 77°F). Protect from freezing.

See FDA-approved patient labeling (Patient Information and Instructions for Use).

Activities Requiring Mental Alertness

Somnolence has been reported in some patients taking Astelin Nasal Spray. Caution patients against engaging in hazardous occupations requiring complete mental alertness and motor coordination such as driving or operating machinery after administration of Astelin Nasal Spray [see Warnings and Precautions (5.1) ].

Concurrent Use of Alcohol and other Central Nervous System Depressants

Instruct patients to avoid concurrent use of Astelin Nasal Spray with alcohol or other central nervous system depressants because additional reductions in alertness and additional impairment of central nervous system performance may occur [see Warnings and Precautions (5.1) ].

Common Adverse Reactions

Inform patients that the treatment with Astelin Nasal Spray may lead to adverse reactions, which include bitter taste, headache, somnolence, dysesthesia, rhinitis, nasal burning, pharyngitis, epistaxis, sinusitis, paroxysmal sneezing, nausea, dry mouth, fatigue, dizziness, and weight increase [see Adverse Reactions (6.1) ].

Priming

Instruct patients to prime the pump before initial use and when Astelin Nasal Spray has not been used for 3 or more days [see Dosage and Administration (2.3) ].

Keep Spray Out of Eyes

Instruct patients to avoid spraying Astelin Nasal Spray into their eyes.

Keep Out of Children’s Reach

Instruct patients to keep Astelin Nasal Spray out of the reach of children. If a child accidentally ingests Astelin Nasal Spray, seek medical help or call a poison control center immediately.

PATIENT INFORMATION

Astelin [AS-ta-LIN](azelastine hydrochloride)Nasal Spray

What is Astelin Nasal Spray?

It is not known if Astelin Nasal Spray is safe and effective in children with seasonal allergic rhinitis under 5 years of age or in children with vasomotor rhinitis under 12 years of age.

What should I tell my healthcare provider before using Astelin Nasal Spray?

Before using Astelin Nasal Spray, tell your healthcare provider if you are:

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Astelin Nasal Spray and other medicines may affect each other, causing side effects.

How should I use Astelin Nasal Spray?

What should I avoid while using Astelin Nasal Spray?

Astelin Nasal Spray can cause sleepiness:

What are the possible side effects of Astelin Nasal Spray?

The most common side effects of Astelin Nasal Spray include:

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all of the possible side effects of Astelin Nasal Spray. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store Astelin Nasal Spray?

Keep Astelin Nasal Spray and all medicines out of reach of children.

General information about the safe and effective use of Astelin Nasal Spray.

Medicines are sometimes prescribed for conditions other than those listed in a Patient Information leaflet. Do not use Astelin Nasal Spray for a condition for which it was not prescribed. Do not give Astelin Nasal Spray to other people, even if they have the same symptoms that you have. It may harm them.

This Patient Information leaflet summarizes the most important information about Astelin Nasal Spray. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about Astelin Nasal Spray that is written for health professionals.

For more information call 1-866-210-5954.

What are the ingredients in Astelin Nasal Spray?

Active ingredient: azelastine hydrochloride

Inactive ingredients: benzalkonium chloride, edetate disodium, hypromellose, citric acid, dibasic sodium phosphate, sodium chloride, and purified water.

 

 

Instructions for Use Astelin [AS-ta-LIN] (azelastine hydrochloride) Nasal Spray

For the correct dose of medicine:

Figure A identifies the parts of your Astelin Nasal Spray pump

Before you use Astelin Nasal Spray for the first time, you will need to prime the bottle.

Priming your Astelin Nasal Spray

Remove the blue dust cover over the tip of the pump and the blue safety clip just under the "shoulders" of the pump (See Figure B ).

Hold the bottle upright with 2 fingers on the shoulders of the spray pump unit and

Now your pump is primed and ready to use.

Using your Astelin Nasal Spray

Step 1. Blow your nose to clear your nostrils.

Step 2. Keep your head tilted downward toward your toes.

Step 3. Place the spray tip about ¼ inch to ½ inch into 1 nostril. Hold bottle upright and aim the spray tip toward the back of your nose (See Figure D ).

Step 4. Close your other nostril with a finger. Press the pump 1 time and sniff gently at the same time, keeping your head tilted forward and down (See Figure E ).

Step 5. Repeat Step 3 and Step 4 in your other nostril.

Step 6. If your healthcare provider tells you to use 2 sprays in each nostril, repeat Steps 2 through 4 above for the second spray in each nostril.

Step 7. Breathe in gently, and do not tilt your head back after using Astelin Nasal Spray. This will help to keep the medicine from going into your throat.

Step 8. When you finish using your Astelin Nasal Spray, wipe the spray tip with a clean tissue or cloth. Put the safety clip and dust cover back on the bottle.

Cleaning the Spray Tip of your Astelin Nasal Spray

This Patient Information and Instructions for Use has been approved by the U.S. Food and Drug Administration.

Manufactured for:MEDA PharmaceuticalsSomerset, NJ 08873-4120©2018 Mylan Specialty LP

Astelin is a registered trademark of Meda Pharmaceuticals Inc., a Mylan company

U.S. Patent D447,419IN-023S6-11      Revised: 9/2018

Important: For use in your nose only.
Important: For use in your nose only.

NDC 0037-0241-30

30 mL

Astelin Nasal Spray 137 mcg (azelastine HCl)

200 Metered Sprays

FOR INTRANASAL USE ONLY DO NOT SPRAY IN EYES    Rx Only

Each spray delivers 0.137 mL(137 mcg azelastine hydrochloride).

U.S. Patents 5,164,194; D447,419.

LB-023S6-08     Rev. 4/08

IMPORTANT: READ ACCOMPANYINGDIRECTIONS CAREFULLYBEFORE USE.

Usual Dosage: See accompanyingfull prescribing information.

Initial priming is 4 sprays; use 2sprays or until a fine mistappears to reprime.

Also contains sodium chloride, dibasicsodium phosphate, hypromellose, edetatedisodium, citric acid, benzalkonium chloride,and purified water (pH 6.8).

Store upright at controlled room temperature20°-25°C (68°-77°F). Protect fromfreezing.

Keep bottle upright, tightly closed, and awayfrom children.

Manufactured byMeda PharmaceuticalsMeda Pharmaceuticals Inc.Somerset, New Jersey 08873-4120

©2008 Meda Pharmaceuticals Inc.

Manufacturer

Meda Pharmaceuticals Inc.

Active Ingredients

Source

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Astepro [meda pharmaceuticals]

These highlights do not include all the information needed to use ASTEPRO safely and effectively. See full prescribing information for ASTEPRO. ASTEPRO (azelastine hydrochloride) nasal spray, for int...

Astelin [physicians total care, inc.]

ASTELIN (azelastine hydrochloride) Nasal Spray, 137 mcg IN-023S6-07 Rev. 1/09 For Intranasal Use Only

Azelastine hydrochloride [wallace pharmaceuticals inc.]

These highlights do not include all the information needed to use Azelastine Hydrochloride safely and effectively. See full prescribing information for Azelastine Hydrochloride. Azelastine Hydrochlori...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis

The purpose of this study is to examine safety and efficacy of Patanase and Astelin in treating the symptoms of non-allergic vasomotor rhinitis (VMR).

Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis

The purpose of this study is to determine if Astepro Nasal Spray (0.1% azelastine hydrochloride) is as safe as Astelin Nasal Spray (0.1% azelastine hydrochloride)

Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis

The primary objective of this study was to compare Placebo to Captisol-Enabled Budesonide + Azelastine in a single spray and two separate sprays (Budesonide + Azelastine) in patients with ...

PubMed Articles [0 Results]

None

Quick Search

Relevant Topics

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Ophthalmology
Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record